The medicines industry is in a period of change. While small molecule therapeutics still make up 90% of approved medicines, patient expectations are driving the industry towards targeted, precision treatments, which require a shift towards stratified, complex medicines with more challenging discovery and development needs.
MDC Connects 2021: A Guide to Complex Medicines is a series of webinars exploring the opportunities and challenges presented by this new class of medicines, and takes you through the steps to take an idea from concept to the clinic.
Here experts describe how to establish preclinical safety and efficacy data for complex medicines and how this compares with conventional drug discovery.
Agenda
Determining efficacy in vivo – Jenny Worthington (Axis Bio)
Physicochemical characterisation: new and novel approaches to understand the pharmacokinetics of complex drugs – Juliana Maynard (MDC)
Do complex medicines raise different challenges from a safety perspective? – Richard Knight (ApconiX)
Recording
Slides
Determining efficacy in vivo
Physicochemical characterisation: new and novel approaches to understand the pharmacokinetics of complex drugs
Do complex medicines raise different challenges from a safety perspective?
Continue through the MDC Connects 2021: A Guide to Complex Medicines journey to get a full insight into this new class of medicines – register to the webinars.
